Interim Report 1 January – 31 March 2022
A successful quarter!
AddLife´s interim report for Q1 2022 is now available online at the company website. The interim report can be downloaded in pdf version.
Visit reports-en.add.life/interim-report-q1-2022
1 JANUARY – 31 MARCH 2022 (3 MONTHS)
- Net sales increased by 49 percent to SEK 2,579m (1,736), of which acquired growth amounted to 51 percent. The organic growth, excluding net sales related to COVID-19, was 5 percent. The COVID-19 related net sales decreased by 25 percent.
- EBITA increased by 34 percent to SEK 435m (326), corresponding to an EBITA-margin of 16.9 percent (18.8).
- Profit after tax decreased by 0.9 percent to SEK 225m (226).
- Earnings per share amounted to SEK 1.85 (2.01). Earnings per share for the last 12 months amounted to SEK 5.91 (6.16).
- Cash flow from operating activities amounted to SEK 332m (184).
- The equity ratio was 37 percent (40).
- Return on working capital (P/WC) amounted to 86 percent (95).
- During the quarter, the previously announced acquisitions of MBA Incorporado S.L and Telia Health Monitoring were completed and after the end of the quarter, two more acquisitions, BioCat GmBh and O'Flynn Medical Ltd, were completed. In total, these acquisitions are estimated to contribute with annual net sales of approximately SEK 830m and approximately 350 employees.
- From 3 January 2022, AddLife AB's share has been moved to the Large Cap segment on Nasdaq Stockholm's market.
- AddLife's president and CEO Kristina Willgård has announced her resignation and after the end of the quarter, Fredrik Dalborg was appointed new President and CEO. Fredrik starts during the fourth quarter.
Stockholm, 28 April 2022
AddLife AB (publ)
For more information, contact;
Kristina Willgård, CEO, [email protected], +46 70 510 12 23
Martin Almgren, CFO, [email protected], +46 70 228 15 45
www.add.life
Teleconference
Investors, analysts and the media are invited to a teleconference at which CEO Kristina Willgård will present the interim report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions. The meeting will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.
The teleconference will be at 10 a.m. on 28 April 2022
If you wish to participate via teleconference, please follow this link>>
Or call in (only sound) +46 8 505 376 58 Conference-ID: 862 373 160#
The presentation is also available on AddLife YouTube >>
AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 2,200 employees in some 85 operating subsidiaries. The Group currently has net sales of approximately SEK 9 billion. AddLife shares are listed on Nasdaq Stockholm.
This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 28 April 2022 at 07:45 a.m. CET.
